Rapid Micro Biosystems (RPID) Gains from Investment Securities (2020 - 2026)

Rapid Micro Biosystems (RPID) posted Gains from Investment Securities of -$70000.0 for Q1 2026, up 59.3% sequentially from -$172000.0 in Q4 2025.

Rapid Micro Biosystems (RPID) Gains from Investment Securities (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems has reported Gains from Investment Securities for 4 years, with the latest figure at -$70000.0 in Q1 2026.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$70000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$242000.0 (changed N/A YoY) and the FY2025 annual result came in at -$131000.0, changed N/A from the prior year.
Gains from Investment Securities improved to -$70000.0 in Q1 2026 per RPID's latest filing, from -$172000.0 in the prior quarter.
Over five years, Gains from Investment Securities peaked at -$70000.0 in Q1 2026 and troughed at -$172000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn
10	Rapid Micro Biosystems	80.26 Mn	60.49 Mn	1.21 Mn

Download Data